stonks4u
Sign up free
CUE logo

CUE Cue Biopharma, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$34.20
+3.12 (+10.04%)

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion prote…

Market Cap: $89.88Mwww.cuebiopharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 14Aug 14

Quote

Day Range
$31.29 – $34.60
52-Week Range
$4.98 – $45.50
Volume
$152.1K
Market Cap
$89.88M
50-Day Avg
$29.53
200-Day Avg
$18.37
Prev Close
$31.08
Open
$31.29

Valuation & Ratios

P/E Ratio
-1.09
EPS
$-8.42
P/B Ratio
1.09
P/S Ratio
1.05
Debt/Equity
0.16
Current Ratio
2.74
Dividend Yield
+0.0%
Gross Margin
+100.0%

Returns & Efficiency

Return on Equity
-100.6%
Return on Assets
-63.0%
FCF Yield
-75.6%
EV/EBITDA
-0.27

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$27.47M$-26.60M$-8.40
2024$9.29M$-40.67M$-21.60
2023$5.49M$-50.73M$-33.30
2022$1.25M$-53.01M$-44.70
2021$14.94M$-44.16M$-42.30

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-1.91 per share

5of 7 quarters beat consensus

Typical surprise +30.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-24.14 vs $-1.69miss
  • Thu, May 14$-1.08 vs $-3.30beat
  • Mon, Mar 16$0.30 vs $-2.70beat
  • Wed, Nov 12$-0.07 vs $-0.10beat
  • Tue, Aug 12$-0.09 vs $-0.13beat
  • Mon, May 12$-0.17 vs $-0.14miss

Estimates and results for CUE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

CUEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·1d ago·Neutral

    Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.

    View source ↗